Quarterly ResultAug 11, 2026, 04:14 PM
Aquestive Q2 Revenue Up 38% to $13.8M; Anaphylm NDA on Track
AI Summary
Aquestive Therapeutics reported Q2 2026 financial results, with total revenue increasing 38% to $13.8 million. The company posted a net loss of $22.9 million, primarily due to an $11.7 million one-time loss on extinguishment of debt, though non-GAAP adjusted EBITDA loss improved to $5.2 million. Aquestive remains on track to resubmit its Anaphylm NDA to the FDA in Q3 2026 after successfully completing required studies, and plans to begin ex-U.S. filings in Q4 2026. The company also provided updates on its AQST-108 program and Libervant's tentative approval status.
Key Highlights
- Total revenue increased 38% to $13.8 million in Q2 2026 from $10.0 million in Q2 2025.
- Net loss for Q2 2026 was $22.9 million, or $0.18 per share, compared to $13.5 million in Q2 2025.
- Non-GAAP adjusted EBITDA loss improved to $5.2 million in Q2 2026 from $9.3 million in Q2 2025.
- Cash and cash equivalents stood at $98.5 million as of June 30, 2026.
- Anaphylm NDA resubmission to the FDA remains on track for Q3 2026.
- Successfully completed human factors validation and pharmacokinetic studies for Anaphylm.
- On track to begin ex-U.S. filings for Anaphylm in Q4 2026.
- Libervant is tentatively approved for epilepsy patients 12+ years, awaiting full approval in January 2027.
Price Impact
More from AQST